Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.835 – $0.922
Volume13,879
Market cap$7M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for IMRN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for IMRN.
Recent news
Company coverage with links to the original publishers.
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced it has engaged LifeSci Capital as its exclusive financial advisor to evaluate strategic initiatives aimed at maximizing shareholder value. These initiatives may include mergers, acquisitions, licensing, or other strategic transactions. The company will not provide updates unless the Board approves a specific transaction or disclosure is deemed appropriate.
Immuron Limited announced that Chief Executive Officer Steven Lydeamore will present virtually at the Emerging Growth Conference on October 28, 2026. The presentation will focus on the company's biopharmaceutical pipeline, including its lead product Travelan® for travelers' diarrhea, IMM-529 for Clostridioides difficile infection, and the ProIBS® distribution agreement in Australia and New Zealand.
Immuron Limited announced FY26 unaudited sales of AUD$7.7 million, up 6% year-over-year, driven by growth in Australia (+10%) and the USA (+7% AUD, +13% USD) for its Travelan® product. Australia's growth was attributed to increased digital marketing, same-store growth, and new retail placements, while US growth benefited from improved Amazon presence and social media initiatives. Canada showed exceptional Q4 growth of 427% on prior comparative period following pipeline fill in FY25, though full-year Canada sales declined 55% due to timing of initial stocking.
Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for IMM-529, its investigational polyclonal antibody treatment for Clostridioides difficile infection (CDI). The company has FDA approval for the IND application and is preparing for Phase 2 clinical trials in Australia. Based on market assessments, IMM-529 could generate projected annual revenues of US$400M if efficacious, with potential partnership deals ranging from US$1-50M upfront plus significant milestone payments and royalties.
Immuron Limited announced Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by growth in Australia (+15%), Canada (+82% quarter-over-quarter), and the USA (+1%). The company attributed growth to increased digital marketing, new retail partnerships, and brand awareness initiatives for its Travelan® product across all regions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.